⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2631205 | 0.72 | — | — | |
| SCHEMBL2228600 | 0.72 | ALDH1A1 (0.40) | — | |
| SCHEMBL46366 | 0.72 | LMNA (0.33) | — | |
| SCHEMBL17420615 | 0.72 | ALDH1A1 (0.31) | — | |
| SCHEMBL372402 | 0.72 | LMNA (0.32) | — | |
| SCHEMBL13474552 | 0.72 | — | — | |
| SCHEMBL2228596 | 0.72 | — | — | |
| SCHEMBL19115283 | 0.72 | — | — | |
| SCHEMBL1304229 | 0.72 | — | — | |
| SCHEMBL4679698 | 0.72 | GPR119 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4573094-A2 | CDK2 INHIBITORS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024175114-A1 | BORON CONTAINING COMPOUNDS AND THERAPEUTIC USES THEREOF | Shanghai Yuyao Biotech Ltd. (CN) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024155601-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240174665-A1 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2024039903-A2 | CDK2 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2008124878-A1 | NON-STEROIDAL COMPOUNDS | CRYPTOPHARMA PTY LTD (AU) | 2008-10-23 | — | — | WO | disclosed |
| US-5536725-A | Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines | FMC CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |